A first step towards a global nomogram to predict disease progression for men on active surveillance

Translational Oncology & Urology Research (TOUR), School of Cancer and Pharmaceutical Sciences, King’s College London, London, UK; Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, USA; Department of Urology, Erasmus University Medical Center, Rotterdam, The Netherlands; Cabrini Institute, Malvern, Australia; Department of Urology, Helsinki University and Helsinki University Hospital, Helsinki, Finland; Department of Urology, Sengkang General Hospital and Singapore General Hospital, Singapore, Singapore; Academic Urology Group, Department of Surgery and Oncology, University of Cambridge, Cambridge, UK Contributions: (I) Conception and design: MW Kattan, MJ Roobol, J Helleman, D Nieboer, M Van Hemelrijck, X Ji; (II) Administrative support: J Helleman, MJ Roobol; (III) Provision of study materials or patients: J Helleman, MJ Roobol, D Nieboer, C Bangma, M Frydenberg, A Rannikko, LS Lee, V Gnanapragasam, MW Kattan, Movember Foundation’s Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium; (IV) Collection and assembly of data: D Nieboer; (V) Data analysis and interpretation: D Nieboer, X Ji, M Van Hemelrijck, MJ Roobol, MW Kattan; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. Correspondence to: Prof. Mieke Van Hemelrijck. Translational Oncology & Urology Research (TOUR), School of Cancer and Pharmaceutical Sciences, King’s College London, Guy’s Hospital, 3rd Floor Bermondsey Wing, London SE1 9RT, UK. Email: Mieke.vanhemelrijck@kcl.ac.uk.